SPATC1L

Summary

SPATC1L (spermatogenesis and centriole associated 1 like, HGNC:1298) is a protein-coding gene on chromosome 21q22.3, encoding Speriolin-like protein (Q9H0A9).

Enables identical protein binding activity. Predicted to be involved in spermatogenesis. Predicted to act upstream of or within actin polymerization or depolymerization; positive regulation of cAMP-dependent protein kinase activity; and positive regulation of cAMP/PKA signal transduction. Located in cytoplasm.

Source: NCBI Gene 84221 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hearing loss disorder (Moderate, GenCC)
• Clinical variants (ClinVar): 99 total
• MANE Select transcript: NM_001142854

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1298
Approved symbol	SPATC1L
Name	spermatogenesis and centriole associated 1 like
Location	21q22.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000160284
Ensembl biotype	protein_coding
OMIM	612412
Entrez	84221

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000291672, ENST00000330205, ENST00000872417, ENST00000872418, ENST00000872419, ENST00000872420, ENST00000967863, ENST00000967864

RefSeq mRNA: 2 — MANE Select: NM_001142854 NM_001142854, NM_032261

CCDS: CCDS13732, CCDS46653

Canonical transcript exons

ENST00000291672 — 5 exons

Exon	Start	End
ENSE00001051147	46161916	46162067
ENSE00001309448	46184356	46184459
ENSE00002117665	46161160	46161705
ENSE00002281221	46182624	46183774
ENSE00003479913	46168308	46168658

Expression profiles

Bgee: expression breadth ubiquitous, 136 present calls, max score 92.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.6371 / max 379.7846, expressed in 1702 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
190913	24.6032	1702
190909	0.0275	7
190908	0.0064	2

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	92.73	gold quality
left testis	UBERON:0004533	92.02	gold quality
testis	UBERON:0000473	91.36	gold quality
left adrenal gland cortex	UBERON:0035825	87.35	gold quality
prostate gland	UBERON:0002367	86.28	gold quality
right adrenal gland cortex	UBERON:0035827	86.21	gold quality
putamen	UBERON:0001874	86.20	gold quality
temporal lobe	UBERON:0001871	85.92	gold quality
amygdala	UBERON:0001876	85.84	gold quality
right adrenal gland	UBERON:0001233	85.10	gold quality
nucleus accumbens	UBERON:0001882	85.02	gold quality
Ammon’s horn	UBERON:0001954	84.78	gold quality
superior frontal gyrus	UBERON:0002661	84.47	gold quality
apex of heart	UBERON:0002098	84.43	gold quality
caudate nucleus	UBERON:0001873	84.36	gold quality
left adrenal gland	UBERON:0001234	83.96	gold quality
anterior cingulate cortex	UBERON:0009835	83.55	gold quality
hypothalamus	UBERON:0001898	83.53	gold quality
right frontal lobe	UBERON:0002810	83.38	gold quality
cerebral cortex	UBERON:0000956	83.14	gold quality
frontal cortex	UBERON:0001870	83.04	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.80	gold quality
prefrontal cortex	UBERON:0000451	82.79	gold quality
brain	UBERON:0000955	82.29	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.08	gold quality
mucosa of stomach	UBERON:0001199	81.65	gold quality
adrenal gland	UBERON:0002369	81.30	gold quality
adenohypophysis	UBERON:0002196	81.27	gold quality
pituitary gland	UBERON:0000007	81.06	gold quality
substantia nigra	UBERON:0002038	80.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting SPATC1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3960	99.41	66.11	96
HSA-MIR-5194	96.77	63.91	1021
HSA-MIR-6738-5P	96.33	63.61	815
HSA-MIR-6734-5P	95.70	65.56	950
HSA-MIR-1914-3P	95.07	63.37	762

Literature-anchored findings (GeneRIF, showing 7)

• rs1465567 of EGFLAM and rs113710653 of SPATC1L may be susceptibility loci for true aortic aneurysm and rs143881017 of RNASE13 may be such a locus for dissecting aortic aneurysm in Japanese individuals. (PMID:28339009)
• TNFSF13, SPATC1L, SLC22A25 and SALL4 may thus be novel susceptibility loci for atrial fibrillation in the Japanese population (PMID:28849223)
• these results implicate the SPATC1L-PKA complex in maintaining the stability of the sperm head-tail junction, thereby revealing a new molecular basis for sperm head-tail integrity. (PMID:30026308)
• SPATC1L was identified as a candidate gene for early-onset and age-related hearing loss. (PMID:30177775)
• PTSD is associated with increased DNA methylation across regions of HLA-DPB1 and SPATC1L. (PMID:33152445)
• Biallelic mutations in spermatogenesis and centriole-associated 1 like (SPATC1L) cause acephalic spermatozoa syndrome and male infertility. (PMID:34213489)
• Balanced chromosomal rearrangements implicate YIPF5 and SPATC1L in non-obstructive oligoasthenozoospermia and oligozoospermia and of a derivative chromosome 22 in recurrent miscarriage. (PMID:37625567)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Spatc1l	ENSMUSG00000009115

Paralogs (1): SPATC1 (ENSG00000186583)

Protein

Protein identifiers

Speriolin-like protein — Q9H0A9 (reviewed: Q9H0A9)

Alternative names: Spermatogenesis and centriole-associated protein 1-like protein

All UniProt accessions (1): Q9H0A9

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Miscellaneous. Highly variable expression among individuals is associated with differential sensitivity to the DNA alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), decreased expression being associated with increased sensitivity.

Similarity. Belongs to the speriolin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H0A9-1	1	yes
Q9H0A9-2	2

RefSeq proteins (2): NP_001136326, NP_115637 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026715	SPATC1	Family
IPR029384	Speriolin_C	Domain
IPR029385	Speriolin_N	Domain

Pfam: PF15058, PF15059

UniProt features (9 total): region of interest 2, modified residue 2, sequence variant 2, chain 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0A9-F1	69.31	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 60, 134

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 55 (showing top): GCANCTGNY_MYOD_Q6, GOBP_MALE_GAMETE_GENERATION, CHANDRAN_METASTASIS_DN, GOCC_MICROTUBULE_ORGANIZING_CENTER, YGACNNYACAR_UNKNOWN, GOBP_ACTIN_FILAMENT_ORGANIZATION, HEN1_01, GOCC_CENTROSOME, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, CCCNNGGGAR_OLF1_01, chr21q22, E2A_Q2, GOMF_PROTEIN_KINASE_A_REGULATORY_SUBUNIT_BINDING, GOMF_PROTEIN_KINASE_A_BINDING

GO Biological Process (3): spermatogenesis (GO:0007283), actin polymerization or depolymerization (GO:0008154), positive regulation of cAMP/PKA signal transduction (GO:0141163)

GO Molecular Function (3): protein kinase A regulatory subunit binding (GO:0034237), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), centrosome (GO:0005813), sperm head-tail coupling apparatus (GO:0120212)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
developmental process involved in reproduction	1
male gamete generation	1
actin filament organization	1
cAMP/PKA signal transduction	1
regulation of cAMP/PKA signal transduction	1
positive regulation of intracellular signal transduction	1
protein kinase A binding	1
protein binding	1
binding	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1

Protein interactions and networks

STRING

716 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPATC1L	PM20D1	Q6GTS8	626
SPATC1L	SPATA6	Q9NWH7	594
SPATC1L	PMFBP1	Q8TBY8	581
SPATC1L	SUN5	Q8TC36	531
SPATC1L	KRTCAP3	Q53RY4	511
SPATC1L	TSGA10	Q9BZW7	489
SPATC1L	C21orf58	P58505	475
SPATC1L	CEP112	Q8N8E3	449
SPATC1L	YBEY	P58557	447
SPATC1L	SEPTIN8	Q92599	447
SPATC1L	METTL27	Q8N6F8	446
SPATC1L	TEX9	Q8N6V9	434
SPATC1L	HLA-DPA1	P01905	425
SPATC1L	HIVEP3	Q5T1R4	418
SPATC1L	SLC22A25	Q6T423	417

IntAct

39 interactions, top by confidence:

A	B	Type	Score
FSD2	SPATC1L	psi-mi:“MI:0915”(physical association)	0.600
SPATC1L	FSD2	psi-mi:“MI:0915”(physical association)	0.600
ARL4A	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
TRIM27	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
TCF4	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	IKZF1	psi-mi:“MI:0915”(physical association)	0.560
SIAH1	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	PHC2	psi-mi:“MI:0915”(physical association)	0.560
PNMA1	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	LZTS2	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	ARMC7	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	ARL4A	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	TCF4	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	SIAH1	psi-mi:“MI:0915”(physical association)	0.560
LZTS2	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560
SPATC1L	TRIM27	psi-mi:“MI:0915”(physical association)	0.560
IKZF1	SPATC1L	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (60): SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), SPATC1L (Two-hybrid), LZTS2 (Two-hybrid), FSD2 (Two-hybrid), SPATC1L (Affinity Capture-MS), SPATC1L (Two-hybrid), SPATC1L (Affinity Capture-MS), SPATC1L (Proximity Label-MS), SPATC1L (Two-hybrid)

ESM2 similar proteins: A0A0D9SF12, A0A1B0GVZ6, A2A8T7, A2A9F4, A4IFR0, A6H7B4, A6NDZ8, A6NE82, A6NI87, A6NJ08, O76081, O93343, P04289, P0DO92, P24097, P27579, P79348, Q0VD86, Q2HR82, Q2KIL8, Q32LN6, Q5BMD4, Q5R5R7, Q67863, Q68FQ8, Q68US1, Q6AY88, Q6PKN7, Q8BG31, Q8BII1, Q8CF25, Q8K2F3, Q8N4L4, Q8NHZ7, Q8TAG6, Q8TDR4, Q8VC23, Q8VHZ9, Q8WUB2, Q8WWY6

Diamond homologs: Q148B6, Q76KD6, Q9D9W0, Q9H0A9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

751 predictions. Top by Δscore:

Variant	Effect	Δscore
21:46162064:ATCT:A	acceptor_gain	1.0000
21:46162066:CT:C	acceptor_gain	1.0000
21:46162067:TC:T	acceptor_loss	1.0000
21:46162068:C:CA	acceptor_loss	1.0000
21:46162068:C:CC	acceptor_gain	1.0000
21:46162063:GATCT:G	acceptor_gain	0.9900
21:46162064:ATCTC:A	acceptor_gain	0.9900
21:46162065:TCTC:T	acceptor_gain	0.9900
21:46162066:CTCTG:C	acceptor_gain	0.9900
21:46168302:CCATA:C	donor_loss	0.9900
21:46168303:CATAC:C	donor_loss	0.9900
21:46168305:TACCA:T	donor_loss	0.9900
21:46168306:A:C	donor_loss	0.9900
21:46168326:T:TA	donor_gain	0.9900
21:46168659:C:CC	acceptor_gain	0.9900
21:46168665:C:CT	acceptor_gain	0.9900
21:46184351:ATCAC:A	donor_loss	0.9900
21:46184352:TCACC:T	donor_loss	0.9900
21:46184353:CACC:C	donor_loss	0.9900
21:46184354:ACCT:A	donor_loss	0.9900
21:46161910:GCGCA:G	donor_loss	0.9800
21:46161911:CGCA:C	donor_loss	0.9800
21:46161912:GCACC:G	donor_loss	0.9800
21:46161913:CAC:C	donor_loss	0.9800
21:46161914:ACC:A	donor_loss	0.9800
21:46161915:C:A	donor_loss	0.9800
21:46168306:A:AC	donor_gain	0.9800
21:46168307:C:CC	donor_gain	0.9800
21:46168666:G:T	acceptor_gain	0.9800
21:46161706:C:CC	acceptor_gain	0.9700

AlphaMissense

2198 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
21:46162004:A:G	L203P	1.000
21:46162009:G:C	F201L	1.000
21:46162009:G:T	F201L	1.000
21:46162011:A:G	F201L	1.000
21:46161554:C:T	G283E	0.999
21:46161949:G:C	F221L	0.999
21:46161949:G:T	F221L	0.999
21:46161951:A:G	F221L	0.999
21:46161976:G:C	F212L	0.999
21:46161976:G:T	F212L	0.999
21:46161977:A:G	F212S	0.999
21:46161978:A:G	F212L	0.999
21:46161998:C:G	R205P	0.999
21:46162013:G:T	A200D	0.999
21:46162019:T:A	E198V	0.999
21:46162022:C:A	G197V	0.999
21:46162022:C:T	G197D	0.999
21:46162023:C:A	G197C	0.999
21:46162023:C:G	G197R	0.999
21:46161384:A:G	W340R	0.998
21:46161384:A:T	W340R	0.998
21:46161389:A:G	F338S	0.998
21:46161427:G:C	C325W	0.998
21:46161569:A:G	L278P	0.998
21:46161950:A:G	F221S	0.998
21:46161953:C:A	G220V	0.998
21:46161953:C:T	G220D	0.998
21:46161995:C:G	R206P	0.998
21:46162001:T:A	D204V	0.998
21:46162001:T:G	D204A	0.998

dbSNP variants (sampled 300 via entrez): RS1000205608 (21:46178901 A>C,G), RS1000245231 (21:46165936 C>A,T), RS1000907753 (21:46179920 G>C), RS1000946724 (21:46177613 G>A), RS1001003017 (21:46161174 T>G), RS1001026101 (21:46173633 G>A), RS1001111991 (21:46166216 AT>A), RS1001159468 (21:46160970 G>A,C,T), RS1001237002 (21:46180137 C>G,T), RS1001552831 (21:46182788 C>G,T), RS1001573425 (21:46177067 A>G), RS1001665963 (21:46163957 G>A), RS1001673667 (21:46171224 C>T), RS1001697311 (21:46171065 G>A,C), RS1001842723 (21:46164676 C>T)

Disease associations

OMIM: gene MIM:612412 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
hearing loss disorder	Moderate	Autosomal recessive

Mondo (1): hearing loss disorder (MONDO:0005365)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
uranyl acetate	affects expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenicals	increases expression	1
Benzo(a)pyrene	affects methylation	1
Copper	affects binding, decreases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Silicon Dioxide	increases expression	1
Thimerosal	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Uranium	affects expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
NCT01109576	EARLY_PHASE1	COMPLETED	Workshops for Veterans With Vision and Hearing Loss